Earnings ·
ImmuCell reports Q2 net income of $1.8M, aided by $2M legal settlement
ICCCImmucell Corp
ImmuCell Corporation reported unaudited financial results for the quarter ended June 30, 2026. Revenue increased 11.5% to $7.2 million, while net income rose to $1.8 million, or $0.20 per diluted share, compared to $0.5 million in the prior year period. The earnings improvement was significantly aided by a one-time $2 million legal settlement payment from a former contract manufacturer. Gross margin declined to 34% due to lower manufacturing volumes and absorbed costs from a discontinued program. Cash on hand increased to $8.9 million, supported by the settlement and operating cash flows of $6.6 million for the first half of the year. The company is an animal health biologics firm that develops, manufactures, and markets products to improve calf health and productivity.